With improved therapies, we can reduce the treatment burden of hemophilia A for patients. Here’s my take on how far we have come and where we are going.
Here’s my take on some of the most exciting hemophilia A studies being presented at the upcoming ASH 2019 meeting in Orlando.
What is the role of pharmacokinetic testing? What is the best option for previously untreated patients? Here’s our take.